Yuki Yoshino
Sendai, 9808575, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 26 publications
Nicaraven enhances the cytotoxicity of X-ray irradiation in cancer cells with homologous recombination deficiency.
Journal: Biochemical and biophysical research communications
Published: November 30, 2024
The centrosome: a critical hub for cell cycle regulation.
Journal: Trends in cell biology
Published: April 15, 2024
Protocol to detect OLA1 polyubiquitination by Aurora A in vivo and in vitro.
Journal: STAR protocols
Published: January 22, 2024
Evaluating homologous recombination activity in tissues to predict the risk of hereditary breast and ovarian cancer and olaparib sensitivity.
Journal: Scientific reports
Published: October 25, 2023
Bevacizumab increases the sensitivity of olaparib to homologous recombination-proficient ovarian cancer by suppressing CRY1 via PI3K/AKT pathway.
Journal: Frontiers in oncology
Published: September 27, 2023
Knockout of Brca1-interacting factor Ola1 in female mice induces tumors with estrogen suppressible centrosome amplification.
Journal: Biochimica et biophysica acta. Molecular basis of disease
Published: September 19, 2023
Aurora A polyubiquitinates the BRCA1-interacting protein OLA1 to promote centrosome maturation.
Journal: Cell reports
Published: January 20, 2023
Paclitaxel sensitizes homologous recombination-proficient ovarian cancer cells to PARP inhibitor via the CDK1/BRCA1 pathway.
Journal: Gynecologic oncology
Published: June 10, 2022
Roles of RACK1 in centrosome regulation and carcinogenesis.
Journal: Cellular signalling
Published: November 10, 2021
Last Updated: 09/26/2026